Clinical Trials Logo

Pancreatic Carcinoma clinical trials

View clinical trials related to Pancreatic Carcinoma.

Filter by:

NCT ID: NCT03164486 Active, not recruiting - Breast Carcinoma Clinical Trials

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Start date: November 2016
Phase: Early Phase 1
Study type: Interventional

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

NCT ID: NCT03137706 Terminated - Clinical trials for Pancreatic Carcinoma

Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

Start date: November 14, 2016
Phase:
Study type: Observational

This pilot research trial studies characterization of mechanical tissue properties in patients with pancreatic, liver, or colon cancer. Mechanical properties and stiffness of the cancerous tissue may be correlated with the standard pathology report that describes the stage of the disease.

NCT ID: NCT03118349 Terminated - Clinical trials for Pancreatic Carcinoma

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Start date: June 1, 2017
Phase: Phase 1
Study type: Interventional

Open label, nonrandomized, dose-escalation with cohort expansion study of MVT-5873/MVT-1075 in subjects with previously treated, Carbohydrate Antigen 19-9 (CA19-9) positive malignancies (e.g., pancreatic adenocarcinoma).

NCT ID: NCT02839954 Recruiting - Clinical trials for Non-small Cell Lung Cancer

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

NCT ID: NCT02807844 Completed - Melanoma Clinical Trials

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Start date: June 29, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

NCT ID: NCT02687230 Terminated - Clinical trials for Pancreatic Carcinoma

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Start date: July 11, 2016
Phase: Phase 1
Study type: Interventional

Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

NCT ID: NCT02683824 Completed - Healthy Subject Clinical Trials

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

Start date: January 12, 2016
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. [18F]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.

NCT ID: NCT02676349 Active, not recruiting - Clinical trials for Pancreatic Carcinoma

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Start date: October 13, 2016
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without preoperative chemoradiotherapy with capecitabine.

NCT ID: NCT02587689 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.

NCT ID: NCT02517268 Completed - Clinical trials for Pancreatic Carcinoma

Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer

WARP
Start date: June 24, 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies accelerated recovery pathway for discharge after surgery in patients with pancreatic cancer. A standardized accelerated recovery pathway may improve outcomes after surgery following complex abdominal operations resulting in a shorter length of stay in patients with pancreatic cancer. It may also help patients to mobilize more quickly and return to the home setting, decrease hospital-acquired infectious complications, and increase potential cost savings. It is not yet known whether an accelerated recovery pathway is better than a standard recovery pathway for discharge following surgery in patients with pancreatic cancer.